Alaunos Therapeutics, Inc.
TCRT
$4.29
$0.2947.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.00K | 9.00K | 6.00K | 6.00K | 6.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00K | 9.00K | 6.00K | 6.00K | 6.00K |
| Cost of Revenue | 239.00K | 248.00K | 1.27M | 4.78M | 9.79M |
| Gross Profit | -229.00K | -239.00K | -1.26M | -4.77M | -9.78M |
| SG&A Expenses | 3.59M | 4.46M | 6.04M | 8.61M | 10.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.17M | 4.82M | 7.42M | 13.51M | 20.57M |
| Operating Income | -4.16M | -4.81M | -7.42M | -13.50M | -20.56M |
| Income Before Tax | -4.07M | -4.68M | -11.78M | -19.13M | -26.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.07 | -4.68 | -11.78 | -19.13 | -26.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.07M | -4.68M | -11.78M | -19.13M | -26.77M |
| EBIT | -4.16M | -4.81M | -7.42M | -13.50M | -20.56M |
| EBITDA | -4.16M | -4.81M | -7.17M | -12.58M | -18.94M |
| EPS Basic | -2.54 | -2.92 | -7.36 | -11.95 | -16.73 |
| Normalized Basic EPS | -1.59 | -1.83 | -2.81 | -5.12 | -8.20 |
| EPS Diluted | -2.54 | -2.92 | -7.36 | -11.95 | -16.73 |
| Normalized Diluted EPS | -1.59 | -1.83 | -2.81 | -5.12 | -8.20 |
| Average Basic Shares Outstanding | 6.41M | 6.41M | 6.41M | 6.40M | 6.40M |
| Average Diluted Shares Outstanding | 6.41M | 6.41M | 6.41M | 6.40M | 6.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |